Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

K, Chayama; S, Takahashi; J, Toyota; Y, Karino; K, Ikeda; H, Ishikawa; H, Watanabe; F, McPhee; E, Hughes; H, Kumada

doi:10.1002/hep.24724

Public

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Shared by NobleBlocks on Jan 30, 2012 • 12:00 AM UTC

Authors:

Chayama K

Takahashi S

Toyota J

Abstract

Unlabelled Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) and ribavirin (RBV) have limited therapeutic options. HCV genotype 1 is the most common worldwide and the most difficult to treat; genotype 1b is the most common subtype of...

Discussions